Economic Impact of Preoperative Meloxicam IV Administration in Total Knee Arthroplasty: A Randomized Trial Sub-Study. (3rd July 2021)

• Record Type: Journal Article
• Authors: Berkowitz, Richard D.; Steinfeld, Richard; Sah, Alexander P.; Anupindi, Vamshi Ruthwik; Shah, Drishti; DeKoven, Mitch; Coyle, Katharine; McCallum, Stewart W.; Mack, Randall; Coyle, Erin; Freyer, Alex; Du, Wei; Black, Libby K.
• Is Part Of: Journal of pain & palliative care pharmacotherapy. Volume 35:Number 3(2021)
• Page Start: 150
• Page End: 162
• Publication Date: 2021-07-03
• Subjects: Total knee arthroplasty -- meloxicam IV -- total hospital costs -- length of stay -- multimodal pain management; Pain -- Treatment -- Periodicals; Analgesia -- Periodicals; Palliative treatment -- Periodicals; Analgesics -- Therapeutic use -- Periodicals; Pain -- drug therapy -- Periodicals; Pain -- prevention & control -- Periodicals; Palliative Care -- Periodicals; Analgesics -- therapeutic use -- Periodicals; 616.994
• DOI: 10.1080/15360288.2021.1883789
• Languages: English
• ISSNs: 1536-0288

Abstract

Abstract: We evaluated the economic impact associated with preoperative meloxicam IV 30 mg vs placebo administration among adult total knee arthroplasty (TKA) recipients enrolled in Phase IIIB NCT03434275 trial. Data on total hospital costs and length of stay (LOS) obtained from the trial were compared between meloxicam IV 30 mg and placebo groups. Patients in the meloxicam IV 30 mg vs placebo group (n = 93 vs 88) incurred an adjusted $2, 266 (95% CI: -$1, 035, $5, 116; p = 0.1689) lower total hospital costs and an adjusted 8.6% (95% confidence interval [CI]: −2.0%, 18.1%; p = 0.1082) shorter LOS. While statistically non-significant, based on 95% CIs, the results from this sub-study may suggest a favorable impact associated with meloxicam IV 30 mg on hospital costs and LOS.